AP Pharma's antinausea drug matches market leader
This article was originally published in Scrip
Executive Summary
AP Pharma is drawing attention to additional data presented on patient-satisfaction derived from its pivotal Phase III for its lead candidate APF530, which is a sustained-release form of the 5HT3 antagonist granisetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV). Data shows that subcutaneous APF530 gives the same level of patient satisfaction and nausea control following chemotherapy over a 5 day period as the market leader, iv palonosetron, regardless of previous patient exposure to chemotherapy, the firm said.